Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-16T15:13:42.343Z Has data issue: false hasContentIssue false

The role of procalcitonin and Clinical Pulmonary for Infection Score (CPIS) score to reduce inappropriate antibiotics use among moderate to severe coronavirus disease 2019 (COVID-19) pneumonia: A quasi-experimental multicenter study

Published online by Cambridge University Press:  22 August 2022

Ornnicha Sathitakorn
Affiliation:
Division of Infectious Diseases, Faculty of Medicine, Thammasat University, Prathum Thani, Thailand
Siriththin Chansirikarnjana
Affiliation:
Division of Infectious Diseases, Lerdsin Hospital, Bangkok, Thailand
Kittiya Jantarathaneewat
Affiliation:
Department of Pharmaceutical Care, Faculty of Pharmacy, Thammasat University, Prathum Thani, Thailand Research Group in Infectious Diseases, Epidemiology, and Prevention, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
David J. Weber
Affiliation:
University of North Carolina, Gillings School of Global Public Health, Chapel Hill, North Carolina, United States
David K. Warren
Affiliation:
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, United States
Piyaporn Apisarnthanarak
Affiliation:
Division of Diagnostic Radiology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Pichaya Tantiyavarong
Affiliation:
Department of Clinical Epidemiology, Faculty of Medicine, Thammasat University, Prathum Thani, Thailand
Anucha Apisarnthanarak*
Affiliation:
Division of Infectious Diseases, Faculty of Medicine, Thammasat University, Prathum Thani, Thailand Research Group in Infectious Diseases, Epidemiology, and Prevention, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
*
Author for correspondence: Anucha Apisarnthanarak, E-mail: anapisarn@yahoo.com

Abstract

In this quasi-experimental study, implementing a procalcitonin and Clinical Pulmonary Infection Score (CPIS) successfully reduced inappropriate antibiotic use among severely-to-critically ill COVID-19 patients, multidrug-resistant organisms, and invasive fungal infections during the intervention period in 2 medical centers. However, this strategy did not improve inappropriate antibiotic use among mildly-to-moderately ill COVID-19 patients.

Type
Concise Communication
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Li, J, Wang, J, Yang, Y, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control 2020;9:153.10.1186/s13756-020-00819-1CrossRefGoogle ScholarPubMed
Calderón-Parra, J, Muiño-Miguez, A, Bendala-Estrada, AD, et al. Inappropriate antibiotic use in the COVID-19 era: factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID. PLoS One 2021;16:e0251340.10.1371/journal.pone.0251340CrossRefGoogle ScholarPubMed
Arastehfar, A, Carvalho, A, van de Veerdonk, FL, et al. COVID-19–associated pulmonary aspergillosis (CAPA)—from immunology to treatment. J Fungi (Basel) 2020;6:91.10.3390/jof6020091CrossRefGoogle ScholarPubMed
Peters, C, Williams, K, Un, EA, et al. Use of procalcitonin for antibiotic stewardship in patients with COVID-19: a quality improvement project in a district general hospital. Clin Med (Lond) 2021;21:7176.10.7861/clinmed.2020-0614CrossRefGoogle Scholar
Sathitakorn, O, Jantarathaneewat, K, Weber, DJ, et al. The feasibility of procalcitonin and CPIS score to reduce inappropriate antibiotics use among severe–critically ill COVID-19 pneumonia patients: a pilot study. Am J Infect Control 2022;50:581584.10.1016/j.ajic.2022.01.030CrossRefGoogle ScholarPubMed
Schurink, CAM. Clinical pulmonary infection score (CPIS) for ventilator-associated pneumonia (VAP). MD+CALC website. https://www.mdcalc.com/clinical-pulmonary-infection-score-cpis-ventilator-associated-pneumonia-vap. Published 2020. Accessed January 1, 2021Google Scholar
Kunin, CM, Tupasi, T, Craig, WA. Use of antibiotics: a brief exposition of the problem and some tentative solutions. Ann Intern Med 1973;79:555560.10.7326/0003-4819-79-4-555CrossRefGoogle ScholarPubMed
Lee, CC, Kwa, ALH, Apisarnthanarak, A, et al. Procalcitonin (PCT)-guided antibiotic stewardship in Asian-Pacific countries: adaptation based on an expert consensus meeting. Clin Chem Lab Med 2020;58:19831991.10.1515/cclm-2019-1122CrossRefGoogle Scholar
Wei, PF. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chin Med J (Engl) 2020;133:10871095.Google Scholar
Singh, N, Rogers, P, Atwood, CW, Wagener, MM, Yu, VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000;162:505511.10.1164/ajrccm.162.2.9909095CrossRefGoogle ScholarPubMed
Supplementary material: File

Sathitakorn et al. supplementary material

Sathitakorn et al. supplementary material

Download Sathitakorn et al. supplementary material(File)
File 195.8 KB